___

• 1. Maule, W. J. (2015). Medical uses of marijuana (Cannabis sativa): fact or fallacy? British Journal of Biomedical Science, 72(2), 85-91.[CrossRef]
• 2. Zuardi, A. W. (2006). History of cannabis as a medicine: a review. Brazilian Journal of Psychiatry, 28, 153-157. [CrossRef]
• 3. Kalant, H. (2001). Medicinal use of cannabis: history and current status. Pain Res Manag, 6(2), 80-91. [CrossRef]
• 4. Touw, M. (1981). The Religious and Medicinal Uses of Cannabis in China, India and Tibet. Journal of Psychoactive Drugs, 13(1), 23-34. [CrossRef]
• 5. Pisanti, S., Bifulco, M. (2017). Modern History of Medical Cannabis: From Widespread Use to Prohibitionism and Back. Trends in Pharmacological Sciences, 38(3), 195-198. [CrossRef]
• 6. Amin, M. R., Ali, D. W. (2019). Pharmacology of Medical Cannabis. Adv Exp Med Biol, 1162, 151-165. [CrossRef]
• 7. Turan, M., (2000). Lif Bitkileri. Bursa: Uludağ Üniversitesi Ziraat Fakültesi Tarla Bitkilleri Bölümü,.
• 8. Aydoğan, M., Terzı̇, Y. E., Gizlenci, Ş., Acar, M., Esen, A., Meral, H. (2020). Türkiye’de kenevir yetiştiriciliğinin ekonomik olarak yapılabilirliği: Samsun ili Vezirköprü ilçesi örneği. ANADOLU JOURNAL OF AGRICULTURAL SCIENCES, 35, 35-50. [CrossRef]
• 9. Ağar, Osman T. (2019). "Cannabis’e Tarihsel Bir Bakış." Estüdam Halk Sağliği Dergisi , pp.7- 11.
• 10. Koca Çalışkan, U, Yıldırım, S . (2020) "Kenevir Ve Sağlık Alanında Kullanımı" . Journal of Faculty of Pharmacy of Ankara University, 44: 112-136. [CrossRef]
• 11. Onay, A., Yıldırım, H., Ekinci, R. (2020). Kenevir, Cannabis sativa L. Ankara: Palme Yayınevi.
• 12. ElSohly, M. A., Radwan, M. M., Gul, W., Chandra, S., Galal, A. (2017). Phytochemistry of Cannabis sativa L. Prog Chem Org Nat Prod, 103, 1-36. [CrossRef]
• 13. Pertwee, R. G. (2008). The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. British journal of pharmacology, 153(2), 199-215. [CrossRef]
• 14. Crippa, J. A., Zuardi, A. W., Martín-Santos, R., Bhattacharyya, S., Atakan, Z., McGuire, P., Fusar-Poli, P. (2009). Cannabis and anxiety: a critical review of the evidence. Hum Psychopharmacol, 24(7), 515-523. [CrossRef]
• 15. Zuardi, A. W., Morais, S. L., Guimarães, F. S., Mechoulam, R. (1995). Antipsychotic effect of cannabidiol. J Clin Psychiatry, 56(10), 485-486. [CrossRef]
• 16. Mechoulam, R., Peters, M., Murillo-Rodriguez, E., Hanus, L. O. (2007). Cannabidiol--recent advances. Chem Biodivers, 4(8), 1678-1692. [CrossRef]
• 17. Console-Bram, L., Marcu, J., Abood, M. E. (2012). Cannabinoid receptors: nomenclature and pharmacological principles. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 38(1), 4-15. [CrossRef]
• 18. Svíženská, I., Dubový, P., Šulcová, A. (2008). Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures — A short review. Pharmacology Biochemistry and Behavior, 90(4), 501-511. [CrossRef]
• 19. Kendall, D. A., Yudowski, G. A. (2017). Cannabinoid Receptors in the Central Nervous System: Their Signaling and Roles in Disease. Frontiers in Cellular Neuroscience, 10(294). [CrossRef]
• 20. Szulakowska, A., Milnerowicz, H. (2007). Cannabis sativa in the Light of Scientific Research. Advances in Clinical and Experimental Medicine, 16, 807-815.
• 21. Onaivi, E. S., Ishiguro, H., Gong, J.-P., Patel, S., Perchuk, A., Meozzi, P. A., Uhl, G. R. (2006). Discovery of the Presence and Functional Expression of Cannabinoid CB2 Receptors in Brain. Annals of the New York Academy of Sciences, 1074(1), 514-536. [CrossRef]
• 22. Van Sickle, M. D., Duncan, M., Kingsley, P. J., Mouihate, A., Urbani, P., Mackie, K., Sharkey, K. A. (2005). Identification and Functional Characterization of Brainstem Cannabinoid CB₂ Receptors. Science, 310(5746), 329-332. [CrossRef]
• 23. Henstridge, C. M. (2012). Off-Target Cannabinoid Effects Mediated by GPR55. Pharmacology, 89(3-4), 179-187. [CrossRef]
• 24. Katchan, V., David, P.,Shoenfeld, Y. (2016). Cannabinoids and autoimmune diseases: A systematic review. Autoimmunity Reviews, 15(6), 513-528. [CrossRef]
• 25. Laprairie, R. B., Bagher, A. M., Denovan-Wright, E. M. (2017). Cannabinoid receptor ligand bias: implications in the central nervous system. Current Opinion in Pharmacology, 32, 32-43. [CrossRef]
• 26. Cunha, P., Romão, A., Mascarenhas-Melo, F., Teixeira, H., Reis, F. (2011). Endocannabinoid system in cardiovascular disorders - new pharmacotherapeutic opportunities. Journal of Pharmacy And Bioallied Sciences, 3(3), 350-360. [CrossRef]
• 27. Pagotto, U., Marsicano, G., Cota, D., Lutz, B., Pasquali, R. (2006). The Emerging Role of the Endocannabinoid System in Endocrine Regulation and Energy Balance. Endocrine Reviews, 27(1), 73-100. doi:10.1210/er.2005-0009
• 28. Bridgeman, M. B., Abazia, D. T. (2017). Medicinal Cannabis: History, Pharmacology, And Implications for the Acute Care Setting. P & T : a peer-reviewed journal for formulary management, 42(3), 180-188. [CrossRef]
• 29. Di Marzo, V. (2008). Targeting the endocannabinoid system: to enhance or reduce? Nat Rev Drug Discov, 7(5), 438-455. [CrossRef]
• 30. Pacher, P., Mechoulam, R. (2011). Is lipid signaling through cannabinoid 2 receptors part of a protective system? Progress in Lipid Research, 50(2), 193-211. [CrossRef]
• 31. Hasenoehrl, C., Taschler, U., Storr, M., Schicho, R. (2016). The gastrointestinal tract – a central organ of cannabinoid signaling in health and disease. Neurogastroenterology & Motility, 28(12), 1765-1780. [CrossRef]
• 32. Ligresti, A., Petrocellis, L. D., Marzo, V. D. (2016). From Phytocannabinoids to Cannabinoid Receptors and Endocannabinoids: Pleiotropic Physiological and Pathological Roles Through Complex Pharmacology. Physiological Reviews, 96(4), 1593-1659. [CrossRef]
• 33. Benito, C., Romero, J. P., Tolón, R. M., Clemente, D., Docagne, F., Hillard, C. J., Romero, J. (2007). Cannabinoid CB₁ and CB₂ Receptors and Fatty Acid Amide Hydrolase Are Specific Markers of Plaque Cell Subtypes in Human Multiple Sclerosis. The Journal of Neuroscience, 27(9), 2396. [CrossRef]
• 34. Jean-Gilles, L., Feng, S., Tench, C. R., Chapman, V., Kendall, D. A., Barrett, D. A., Constantinescu, C. S. (2009). Plasma endocannabinoid levels in multiple sclerosis. Journal of the Neurological Sciences, 287(1), 212-215. [CrossRef]
• 35. Killestein, J., Hoogervorst, E. L., Reif, M., Kalkers, N. F., Van Loenen, A. C., Staats, P. G., Polman, C. H. (2002). Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology, 58(9), 1404-1407. [CrossRef]
• 36. Ungerleider, J. T., Andyrsiak, T., Fairbanks, L., Ellison, G. W., Myers, L. W. (1987). Delta-9- THC in the treatment of spasticity associated with multiple sclerosis. Adv Alcohol Subst Abuse, 7(1), 39-50. [CrossRef]
• 37. Zajicek, J. P., Hobart, J. C., Slade, A., Barnes, D., Mattison, P. G. (2012). MUltiple Sclerosis and Extract of Cannabis: results of the MUSEC trial. Journal of Neurology, Neurosurgery & Psychiatry, 83(11), 1125. [CrossRef]
• 38. Collin, C., Ehler, E., Waberzinek, G., Alsindi, Z., Davies, P., Powell, K., Ambler, Z. (2010). A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurological Research, 32(5), 451-459. [CrossRef]
• 39. Wade, D. T., Makela, P., Robson, P., House, H.,Bateman, C. (2004). Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double- blind, randomized, placebo-controlled study on 160 patients. Multiple Sclerosis Journal, 10(4), 434-441. [CrossRef]
• 40. Rog, D. J., Nurmikko, T. J., Young, C. A. (2007). Oromucosal Δ9- tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: An uncontrolled, open-label, 2-year extension trial. Clinical Therapeutics, 29(9), 2068-2079. [CrossRef]
• 41. Wallace, M. J., Blair, R. E., Falenski, K. W., Martin, B. R., DeLorenzo, R. J. (2003). The Endogenous Cannabinoid System Regulates Seizure Frequency and Duration in a Model of Temporal Lobe Epilepsy. Journal of Pharmacology and Experimental Therapeutics, 307(1), 129. [CrossRef]
• 42. Ellison, J. M., Gelwan, E., Ogletree, J. (1990). Complex partial seizure symptoms affected by marijuana abuse. J Clin Psychiatry, 51(10), 439-440. [CrossRef]
• 43. Gross, D. W., Hamm, J., Ashworth, N. L., Quigley, D. (2004). Marijuana use and epilepsy: prevalence in patients of a tertiary care epilepsy center. Neurology, 62(11), 2095-2097. [CrossRef]
• 44. Mortati, K., Dworetzky, B., Devinsky, O. (2007). Marijuana: an effective antiepileptic treatment in partial epilepsy? A case report and review of the literature. Rev Neurol Dis, 4(2), 103-106.
• 45. Hamerle, M., Ghaeni, L., Kowski, A., Weissinger, F., Holtkamp, M. (2014). Cannabis and other illicit drug use in epilepsy patients. European Journal of Neurology, 21(1), 167-170. [CrossRef]
• 46. Hussain, S. A., Zhou, R., Jacobson, C., Weng, J., Cheng, E., Lay, J., Sankar, R. (2015). Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: A potential role for infantile spasms and Lennox–Gastaut syndrome. Epilepsy & Behavior, 47, 138-141. [CrossRef]
• 47. Porter, B. E., Jacobson, C. (2013). Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy. Epilepsy & Behavior, 29(3), 574-577. [CrossRef]
• 48. Gofshteyn, J. S., Wilfong, A., Devinsky, O., Bluvstein, J., Charuta, J., Ciliberto, M. A., Marsh, E. D. (2017). Cannabidiol as a Potential Treatment for Febrile Infection-Related Epilepsy Syndrome (FIRES) in the Acute and Chronic Phases. Journal of Child Neurology, 32(1), 35-40. [CrossRef]
• 49. Suraev, A., Lintzeris, N., Stuart, J., Kevin, R. C., Blackburn, R., Richards, E., McGregor, I. S. (2018). Composition and Use of Cannabis Extracts for Childhood Epilepsy in the Australian Community. Scientific Reports, 8(1), 10154. [CrossRef]
• 50. Stampanoni Bassi M., (2017). Cannabinoids in Parkinson's Disease.. Cannabis and Cannabinoid Research, 2(1), 21-29. [CrossRef]
• 51. Basavarajappa, B. S., Shivakumar, M., Joshi, V., Subbanna, S. (2017). Endocannabinoid system in neurodegenerative disorders. J Neurochem, 142(5), 624-648. [CrossRef]
• 52. Hurley, M. J., Mash, D. C., Jenner, P. (2003b). Expression of cannabinoid CB1 receptor mRNA in basal ganglia of normal and parkinsonian human brain. J Neural Transm (Vienna), 110(11), 1279-1288. [CrossRef]
• 53. Hurley, M. J., Mash, D. C., Jenner, P. (2003a). Expression of cannabinoid CB1 receptor mRNA in basal ganglia of normal and parkinsonian human brain. Journal of Neural Transmission, 110(11), 1279-1288. [CrossRef]
• 54. El Banoua, F., Caraballo, I., Flores, J. A., Galan-Rodriguez, B., Fernandez-Espejo, E. (2004). Effects on turning of microinjections into basal ganglia of D1 and D2 dopamine receptors agonists and the cannabinoid CB1 antagonist SR141716A in a rat Parkinson's model. Neurobiology of Disease, 16(2), 377-385. [CrossRef]
• 55. Kelsey, J. E., Harris, O., Cassin, J. (2009). The CB1 antagonist rimonabant is adjunctively therapeutic as well as monotherapeutic in an animal model of Parkinson's disease. Behavioural Brain Research, 203(2), 304-307. [CrossRef]
• 56. Meschler, J. P., Howlett, A. C., Madras, B. K. (2001). Cannabinoid receptor agonist and antagonist effects on motor function in normal and 1-methyl-4-phenyl-1,2,5,6- tetrahydropyridine (MPTP)-treated non-human primates. Psychopharmacology (Berl), 156(1), 79-85. [CrossRef]
• 57. Benito, C., Núñez, E., Tolón, R. M., Carrier, E. J., Rábano, A., Hillard, C. J., Romero, J. (2003). Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. J Neurosci, 23(35), 11136-11141. [CrossRef]
• 58. Ramírez, B. G., Blázquez, C., del Pulgar, T. G., Guzmán, M., de Ceballos, M. L. (2005). Prevention of Alzheimer's Disease Pathology by Cannabinoids: Neuroprotection Mediated by Blockade of Microglial Activation. The Journal of Neuroscience, 25(8), 1904. [CrossRef]
• 59. Koppel, J., Vingtdeux, V., Marambaud, P., d’Abramo, C., Jimenez, H., Stauber, M., Davies, P. (2014). CB2 Receptor Deficiency Increases Amyloid Pathology and Alters Tau Processing in a Transgenic Mouse Model of Alzheimer’s Disease. Molecular Medicine, 20(1), 29-36. [CrossRef]
• 60. Solas, M., Francis, P. T., Franco, R., Ramirez, M. J. (2013). CB2 receptor and amyloid pathology in frontal cortex of Alzheimer's disease patients. Neurobiology of Aging, 34(3), 805- 808. [CrossRef]
• 61. Tolón, R. M., Núñez, E., Pazos, M. R., Benito, C., Castillo, A. I., Martínez-Orgado, J. A., Romero, J. (2009). The activation of cannabinoid CB2 receptors stimulates in situ and in vitro beta-amyloid removal by human macrophages. Brain Research, 1283, 148-154. [CrossRe]
• 62. Wu, J., Bie, B., Yang, H., Xu, J. J., Brown, D. L., Naguib, M. (2013). Activation of the CB2 receptor system reverses amyloid-induced memory deficiency. Neurobiology of Aging, 34(3), 791-804. [CrossRef]
• 63. Esposito, G., Scuderi, C., Savani, C., Steardo Jr, L., De Filippis, D., Cottone, P.,Steardo, L. (2007). Cannabidiol in vivo blunts β-amyloid induced neuroinflammation by suppressing IL-1β and iNOS expression. British journal of pharmacology, 151(8), 1272-1279. [CrossRef]
• 64. Glass, M., Faull, R. L., Dragunow, M. (1993). Loss of cannabinoid receptors in the substantia nigra in Huntington's disease. Neuroscience, 56(3), 523-527. [CrossRef]
• 65. Richfield, E. K., Herkenham, M. (1994). Selective vulnerability in Huntington's disease: Preferential loss of cannabinoid receptors in lateral globus pallidus. Annals of Neurology, 36(4), 577-584. [CrossRef]
• 66. Denovan-Wright, E. M., Robertson, H. A. (2000). Cannabinoid receptor messenger RNA levels decrease in a subset of neurons of the lateral striatum, cortex and hippocampus of transgenic Huntington's disease mice. Neuroscience, 98(4), 705-713. [CrossRef]
• 67. Dowie, M. J., Bradshaw, H. B., Howard, M. L., Nicholson, L. F., Faull, R. L., Hannan, A. J., Glass, M. (2009). Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease. Neuroscience, 163(1), 456-465. [CrossRef]
• 68. McCaw, E. A., Hu, H., Gomez, G. T., Hebb, A. L., Kelly, M. E., Denovan-Wright, E. M. (2004). Structure, expression and regulation of the cannabinoid receptor gene (CB1) in Huntington's disease transgenic mice. Eur J Biochem, 271(23-24), 4909-4920. [CrossRef]
• 69. Consroe, P., Laguna, J., Allender, J., Snider, S., Stern, L., Sandyk, R., Schram, K. (1991). Controlled clinical trial of cannabidiol in Huntington's disease. Pharmacol Biochem Behav, 40(3), 701-708. [CrossRef]
• 70. López-Sendón Moreno, J. L., García Caldentey, J., Trigo Cubillo, P., Ruiz Romero, C., García Ribas, G., Alonso Arias, M. A. A., García de Yébenes Prous, J. (2016). A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington’s disease. Journal of Neurology, 263(7), 1390-1400. [CrossRef]
• 71. Curtis, A., Mitchell, I., Patel, S., Ives, N., Rickards, H. (2009). A pilot study using nabilone for symptomatic treatment in Huntington's disease. Movement Disorders, 24(15), 2254-2259. [CrossRef]
• 72. Alles, S. R. A., Smith, P. A. (2018). Etiology and Pharmacology of Neuropathic Pain. Pharmacol Rev, 70(2), 315-347. [CrossRef]
• 73. Abrams, D. I., Jay, C. A., Shade, S. B., Vizoso, H., Reda, H., Press, S., . Petersen, K. L. (2007). Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology, 68(7), 515-521. [CrossRef]
• 74. Ellis, R. J., Toperoff, W., Vaida, F., van den Brande, G., Gonzales, J., Gouaux, B., Atkinson, J. H. (2009). Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology, 34(3), 672-680. [CrossRef]
• 75. Wilsey, B., Marcotte, T., Tsodikov, A., Millman, J., Bentley, H., Gouaux, B.,Fishman, S. (2008). A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. The journal of pain : official journal of the American Pain Society, 9(6), 506-521. [CrossRef]
• 76. Borgelt, L. M., Franson, K. L., Nussbaum, A. M., Wang, G. S. (2013). The pharmacologic and clinical effects of medical cannabis. Pharmacotherapy, 33(2), 195-209. [CrossRef]
• 77. Nurmikko, T. J., Serpell, M. G., Hoggart, B., Toomey, P. J., Morlion, B. J., Haines, D. (2007). Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double- blind, placebo-controlled clinical trial. Pain, 133(1-3), 210-220. [CrossRef]
• 78. Rog, D. J., Nurmikko, T. J.,Young, C. A. (2007). Oromucosal delta9- tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial. Clin Ther, 29(9), 2068-2079. [CrossRef]
• 79. Häuser, W., Fitzcharles, M. A., Radbruch, L., Petzke, F. (2017). Cannabinoids in Pain Management and Palliative Medicine. Dtsch Arztebl Int, 114(38), 627-634. [CrossRef]
• 80. Fitzcharles, M. A., Baerwald, C., Ablin, J., Häuser, W. (2016). Efficacy, tolerability and safety of cannabinoids in chronic pain associated with rheumatic diseases (fibromyalgia syndrome, back pain, osteoarthritis, rheumatoid arthritis): A systematic review of randomized controlled trials. Schmerz, 30(1), 47-61. [CrossRef]
• 81. Fitzcharles, M. A., Ste-Marie, P. A., Häuser, W., Clauw, D. J., Jamal, S., Karsh, J.,Walsh, Z. (2016). Efficacy, Tolerability, and Safety of Cannabinoid Treatments in the Rheumatic Diseases: A Systematic Review of Randomized Controlled Trials. Arthritis Care Res (Hoboken), 68(5), 681-688. [CrossRef]
• 82. Fraguas-Sánchez, A. I., Martín-Sabroso, C., Torres-Suárez, A. I. (2018). Insights into the effects of the endocannabinoid system in cancer: a review. British journal of pharmacology, 175(13), 2566-2580. [CrossRef]
• 83. Sredni, S. T., Huang, C.-C., Suzuki, M., Pundy, T., Chou, P., Tomita, T. (2016). Spontaneous involution of pediatric low-grade gliomas: high expression of cannabinoid receptor 1 (CNR1) at the time of diagnosis may indicate involvement of the endocannabinoid system. Child's Nervous System, 32(11), 2061-2067. [CrossRef]
• 84. Wu, X., Han, L., Zhang, X., Li, L., Jiang, C., Qiu, Y., Fu, J. (2012). Alteration of endocannabinoid system in human gliomas. Journal of Neurochemistry, 120(5), 842-849. [CrossRef]
• 85. Ellert-Miklaszewska, A., Grajkowska, W., Gabrusiewicz, K., Kaminska, B., Konarska, L. (2007). Distinctive pattern of cannabinoid receptor type II (CB2) expression in adult and pediatric brain tumors. Brain Res, 1137(1), 161-169. [CrossRef]
• 86. Sánchez, C., de Ceballos, M. L., Gomez del Pulgar, T., Rueda, D., Corbacho, C., Velasco, G.,Guzmán, M. (2001). Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. Cancer Res, 61(15), 5784-5789.
• 87. Schley, M., Ständer, S., Kerner, J., Vajkoczy, P., Schüpfer, G., Dusch, M., Konrad, C. (2009). Predominant CB2 receptor expression in endothelial cells of glioblastoma in humans. Brain Res Bull, 79(5), 333-337. [CrossRef]
• 88. Hohmann, T., Grabiec, U., Ghadban, C., Feese, K., Dehghani, F. (2017). The influence of biomechanical properties and cannabinoids on tumor invasion. Cell adhesion & migration, 11(1), 54-67. [CrossRef]
• 89. Ma, C., Wu, T.-T., Jiang, P.-C., Li, Z.-Q., Chen, X.-J., Fu, K., Gong, R. (2016). Anti- carcinogenic activity of anandamide on human glioma in vitro and in vivo. Molecular medicine reports, 13(2), 1558-1562. [CrossRef]
• 90. Fowler, C. J., Jonsson, K. O., Andersson, A., Juntunen, J., Järvinen, T., Vandevoorde, S., .Smart, D. (2003). Inhibition of C6 glioma cell proliferation by anandamide, 1-arachidonoylglycerol, and by a water soluble phosphate ester of anandamide: variability in response and involvement of arachidonic acid. Biochem Pharmacol, 66(5), 757-767. [CrossRef]
• 91. Jacobsson, S. O., Wallin, T., Fowler, C. J. (2001). Inhibition of rat C6 glioma cell proliferation by endogenous and synthetic cannabinoids. Relative involvement of cannabinoid and vanilloid receptors. J Pharmacol Exp Ther, 299(3), 951-959. [CrossRef]
• 92. Caffarel, M. M., Andradas, C., Mira, E., Pérez-Gómez, E., Cerutti, C., Moreno-Bueno, G., Sánchez, C. (2010). Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition. Mol Cancer, 9, 196. [CrossRef]
• 93. Bisogno, T., Katayama, K., Melck, D., Ueda, N., De Petrocellis, L., Yamamoto, S., Di Marzo, V. (1998). Biosynthesis and degradation of bioactive fatty acid amides in human breast cancer and rat pheochromocytoma cells--implications for cell proliferation and differentiation. Eur J Biochem, 254(3), 634-642. [CrossRef]
• 94. Melck, D., De Petrocellis, L., Orlando, P., Bisogno, T., Laezza, C., Bifulco, M., Di Marzo, V. (2000). Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology, 141(1), 118-126. [CrossRef]
• 95. Ligresti, A., Moriello, A. S., Starowicz, K., Matias, I., Pisanti, S., De Petrocellis, L., Di Marzo, V. (2006). Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J Pharmacol Exp Ther, 318(3), 1375-1387. [CrossRef]
• 96. Qamri, Z., Preet, A., Nasser, M. W., Bass, C. E., Leone, G., Barsky, S. H., Ganju, R. K. (2009). Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer. Mol Cancer Ther, 8(11), 3117-3129. [CrossRef]
• 97. Chung, S. C., Hammarsten, P., Josefsson, A., Stattin, P., Granfors, T., Egevad, L., Fowler, C. J. (2009). A high cannabinoid CB(1) receptor immunoreactivity is associated with disease severity and outcome in prostate cancer. Eur J Cancer, 45(1), 174-182. [CrossRef]
• 98. Cipriano, M., Häggström, J., Hammarsten, P., Fowler, C. J. (2013). Association between Cannabinoid CB1 Receptor Expression and Akt Signalling in Prostate Cancer. PLoS One, 8(6), e65798. [CrossRef]
• 99. Orellana-Serradell, O., Poblete, C. E., Sanchez, C., Castellón, E. A., Gallegos, I., Huidobro, C., Contreras, H. R. (2015). Proapoptotic effect of endocannabinoids in prostate cancer cells. Oncol Rep, 33(4), 1599-1608. [CrossRef]
• 100. Sarfaraz, S., Afaq, F., Adhami, V. M., Mukhtar, H. (2005). Cannabinoid receptor as a novel target for the treatment of prostate cancer. Cancer Res, 65(5), 1635-1641. [CrossRef]
• 101. Mimeault, M., Pommery, N., Wattez, N., Bailly, C., Hénichart, J. P. (2003). Anti-proliferative and apoptotic effects of anandamide in human prostatic cancer cell lines: implication of epidermal growth factor receptor down-regulation and ceramide production. Prostate, 56(1), 1- 12. [CrossRef]
• 102. Nithipatikom, K., Isbell, M. A., Endsley, M. P., Woodliff, J. E., Campbell, W. B. (2011). Anti- proliferative effect of a putative endocannabinoid, 2-arachidonylglyceryl ether in prostate carcinoma cells. Prostaglandins & other lipid mediators, 94(1-2), 34-43. [CrossRef]
• 103. DeMorrow, S., Francis, H., Gaudio, E., Venter, J., Franchitto, A., Kopriva, S., Alpini, G. (2008). The endocannabinoid anandamide inhibits cholangiocarcinoma growth via activation of the noncanonical Wnt signaling pathway. American journal of physiology. Gastrointestinal and liver physiology, 295(6), G1150-G1158. [CrossRef]
• 104. Frampton, G., Coufal, M., Li, H., Ramirez, J., DeMorrow, S. (2010). Opposing actions of endocannabinoids on cholangiocarcinoma growth is via the differential activation of Notch signaling. Experimental cell research, 316(9), 1465-1478. [CrossRef]
• 105. Ramer, R., Schwarz, R., Hinz, B. (2019). Modulation of the Endocannabinoid System as a Potential Anticancer Strategy. Frontiers in pharmacology, 10, 430-430. [CrossRef]
• 106. Vara, D., Salazar, M., Olea-Herrero, N., Guzmán, M., Velasco, G., Díaz-Laviada, I. (2011). Anti-tumoral action of cannabinoids on hepatocellular carcinoma: role of AMPK-dependent activation of autophagy. Cell Death Differ, 18(7), 1099-1111. [CrossRef]
• 107. Xu, D., Wang, J., Zhou, Z., He, Z., Zhao, Q. (2015). Cannabinoid WIN55, 212-2 induces cell cycle arrest and inhibits the proliferation and migration of human BEL7402 hepatocellular carcinoma cells Corrigendum in /mmr/13/1/1054. Mol Med Rep, 12(6), 7963-7970. [CrossRef]
• 108. Sallan, S. E., Zinberg, N. E., Frei, E., 3rd. (1975). Antiemetic effect of delta-9- tetrahydrocannabinol in patients receiving cancer chemotherapy. N Engl J Med, 293(16), 795- 797. [CrossRef]
• 109. Darmani, N. A. (2001b). Delta(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB(1) receptor antagonist/inverse agonist SR 141716A. Neuropsychopharmacology, 24(2), 198-203. [CrossRef]
• 110. Darmani, N. A. (2001a). Delta-9-tetrahydrocannabinol differentially suppresses cisplatin- induced emesis and indices of motor function via cannabinoid CB(1) receptors in the least shrew. Pharmacol Biochem Behav, 69(1-2), 239-249. [CrossRef]
• 111. Pomeroy, M., Fennelly, J. J., Towers, M. (1986). Prospective randomized double-blind trial of nabilone versus domperidone in the treatment of cytotoxic-induced emesis. Cancer Chemother Pharmacol, 17(3), 285-288. [CrossRef]
• 112. Meiri, E., Jhangiani, H., Vredenburgh, J. J., Barbato, L. M., Carter, F. J., Yang, H. M., Baranowski, V. (2007). Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. Curr Med Res Opin, 23(3), 533-543. [CrossRef]
• 113. Polito, S., MacDonald, T., Romanick, M., Jupp, J., Wiernikowski, J., Vennettilli, A., Dupuis, L. L. (2018). Safety and efficacy of nabilone for acute chemotherapy-induced vomiting prophylaxis in pediatric patients: A multicenter, retrospective review. Pediatr Blood Cancer, 65(12), e27374. [CrossRef]
• 114. Kleine-Brueggeney, M., Greif, R., Brenneisen, R., Urwyler, N., Stueber, F., Theiler, L. G. (2015). Intravenous Delta-9-Tetrahydrocannabinol to Prevent Postoperative Nausea and Vomiting: A Randomized Controlled Trial. Anesth Analg, 121(5), 1157-1164. [CrossRef]
• 115. Pellati, F., Borgonetti, V., Brighenti, V., Biagi, M., Benvenuti, S., Corsi, L. (2018). Cannabis sativa L. and Nonpsychoactive Cannabinoids: Their Chemistry and Role against Oxidative Stress, Inflammation, and Cancer. BioMed research international, 2018, 1691428. [CrossRef]
• 116. Costa, B., Colleoni, M., Conti, S., Parolaro, D., Franke, C., Trovato, A. E., Giagnoni, G. (2004). Oral anti-inflammatory activity of cannabidiol, a non-psychoactive constituent of cannabis, in acute carrageenan-induced inflammation in the rat paw. Naunyn-Schmiedeberg's archives of pharmacology, 369(3), 294–299. [CrossRef]
• 117. Petrosino, S., Verde, R., Vaia, M., Allarà, M., Iuvone, T., Di Marzo, V. (2018). Anti- inflammatory Properties of Cannabidiol, a Nonpsychotropic Cannabinoid, in Experimental Allergic Contact Dermatitis. The Journal of pharmacology and experimental therapeutics, 365(3), 652–663. [CrossRef]
• 118. Mackie, K., Stella, N. (2006). Cannabinoid receptors and endocannabinoids: evidence for new players. The AAPS journal, 8(2), E298–E306. [CrossRef]
• 119. Parlakpınar, Hakan Celbis, Osman Ozhan, Onural Petekkaya, Semih Samdanci, Emine Ermis, Necip Koparir, Pelin Soylu, Ozcan Acet, Ahmet. (2016). Cardiovascular effects of JWH-018 from synthetic cannabinoids [Sentetik kannabinoidlerden JWH-018'in kardiyovaskuler etkileri], Medicine Science., 5. 1. [CrossRef]
• 120. Köksoy S , Başalp A . (2021). Effect of synthetic cannabinoids (JWH-018) on antibody response to HBV vaccination, Mehmet Akif Ersoy Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi, 2021; 9(1): 21-26. [CrossRef]
• 121. Kogan, N. M., Mechoulam, R. (2007). Cannabinoids in health and disease. Dialogues in clinical neuroscience, 9(4), 413–430. [CrossRef]
• 122. Wong, K. U., Baum, C. R. (2019). Acute Cannabis Toxicity. Pediatric emergency care, 35(11), 799–804. [CrossRef]
• 123. Kuzucuoğlu, T., Uçkun, S., Temizel, F., Arslan, G., Çevik, B. (2018). Kannabinoid İntoksikasyonlarının Yoğun Bakım Sonuçları: Olgu Serisi. Dahili ve Cerrahi Bilimler Yoğun Bakım Dergisi.; 9(3): 84 - 87. [CrossRef]